TY - JOUR
T1 - Peritoneal Dialysis Guidelines 2019 Part 2
T2 - Main Text (Position paper of the Japanese Society for Dialysis Therapy)
AU - on behalf of the Working Group on Revision of Peritoneal Dialysis Guidelines of the Japanese Society for Dialysis Therapy
AU - Ryuzaki, Munekazu
AU - Ito, Yasuhiko
AU - Nakamoto, Hidetomo
AU - Ishikawa, Yuichi
AU - Itami, Noritomo
AU - Ito, Minoru
AU - Ueda, Atsushi
AU - Kanazawa, Yoshie
AU - Kawanishi, Hideki
AU - Kanno, Yoshihiko
AU - Sugiyama, Hitoshi
AU - Tsuruya, Kazuhiko
AU - Terawaki, Hiroyuki
AU - Tomo, Tadashi
AU - Fukasawa, Mizuya
AU - Yamashita, Akihiro C.
AU - Yokoi, Hideki
AU - Nakayama, Masaaki
AU - Yuasa, Hidemichi
AU - Tsujimoto, Yasushi
AU - Tsujimoto, Hiraku
AU - Saka, Yosuke
AU - Kuroki, Yusuke
AU - Yasuda, Kaoru
AU - Fujii, Takayuki
AU - Kanno, Atsuhiro
AU - Fujikura, Emi
AU - Watanabe, Kimio
AU - Obata, Yoko
AU - Murashima, Miho
AU - Toda, Naohiro
AU - Yamamoto, Shuto
AU - Tsujimoto, Yoshihiro
AU - Sakurada, Tsutomu
AU - Komukai, Daisuke
AU - Uchiyama, Kiyotaka
AU - Washida, Naoki
AU - Morimoto, Kohkichi
AU - Kasai, Takahiro
AU - Maruyama, Yukio
AU - Higuchi, Chieko
AU - Io, Hiroaki
AU - Wakabayashi, Keiichi
AU - Ryuzaki, Munekazu
AU - Minoru, Ito
AU - Tamura, Masahito
AU - Furuzono, Tsutomu
AU - Masakane, Ikuto
AU - Masaki, Hiroya
AU - Matsumura, Mamiko
N1 - Funding Information:
Receives research funding from Daiichi Sankyo Co. (researches, develops, manufactures, and sells prescription drugs), Baxter (imports, manufactures, and sells dialysis products, plasma protein formulations, and drug administration systems), and Mitsubishi Tanabe Pharma Corp. (manufactures and sells mostly prescription drugs).
Funding Information:
Receives research funding from Otsuka Pharmaceutical Co. (manufactures, sells, imports, and exports pharmaceuticals, clinical examinations, medical equipment, and food products), Kyowa Kirin Co. (manufactures and sells prescription drugs), Daiichi Sankyo Co. (researches, develops, manufactures, and sells prescription drugs), Chugai Pharmaceutical Co. (manufactures and sells prescription drugs), Baxter (imports, manufactures, and sells dialysis products, plasma protein formulations, and drug administration systems), and Kaneka Medix Corp. (manufactures and sells medical devices).
Funding Information:
Receives research funding from AstraZeneca KK (develops, manufactures, and sells prescription drugs), Shionogi & Co. (manufactures and sells pharmaceuticals, diagnostic agents, and other products), Baxter (imports, manufactures, and sells dialysis products, plasma protein formulations, and drug administration systems), Astellas Pharma Inc. (manufactures, sells, imports, and exports pharmaceuticals), Kyowa Kirin Co. (manufactures and sells prescription drugs), Takeda Pharmaceutical Co. (manufactures, sells, imports, and exports pharmaceuticals and quasi-drugs), Teijin Pharma Ltd. (researches, develops, and manufactures pharmaceuticals and medical devices), and Ono Pharmaceutical Co. (researches, develops, manufactures, purchases, and sells pharmaceuticals, mainly prescription drugs).
Funding Information:
Receives research funding from Baxter (imports, manufactures, and sells dialysis products, plasma protein formulations, and drug administration systems), Daiichi Sankyo Co. (researches, develops, manufactures, sells prescription drugs), and Mitsubishi Tanabe Pharma Corp. (manufactures and sells pharmaceuticals, mainly prescription drugs).
Funding Information:
Receives research funding from Sanwa Kagaku Kenkyusho Co. (researches, develops, manufactures, and sells pharmaceuticals, diagnostic agents, and other products).
Funding Information:
Receives research funding from Sumitomo Dainippon Pharma Co. (manufactures and sells prescription drugs, diagnostic agents, and other products), Genzyme Corp. (imports, manufactures, and sells pharmaceuticals), and Bayer Yakuhin Ltd. (develops, imports, manufactures, and sells pharmaceuticals, medical devices, and veterinary drugs).
Funding Information:
Literature surveys, conference expenses, transportation expenses, translation fee, etc., were paid for by financial support from the Japanese Society for Dialysis Therapy.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Background: This article is a duplicated publication from the Japanese version of “2019 JSDT Guidelines for Peritoneal Dialysis” with permission from the Japanese Society for Dialysis Therapy (JSDT). This clinical practice guideline (CPG) was developed primarily by the Working Group on Revision of Peritoneal Dialysis (PD) Guidelines of the Japanese Society for Dialysis Therapy. Recently, the definition and creation process for CPGs have become far more rigorous; traditional methods and formats no longer adhere to current standards. To improve the reliability of international transmission of our findings, CPGs are created in compliance with the methodologies developed by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) working group. Part 2 of this PD guideline is the first CPG developed by our society that conforms to the GRADE approach. Methods: Detailed processes were created in accordance with the Cochrane handbook and the GRADE approach developed by the GRADE working group. Results: Clinical question (CQ)1: Is the use of renin-angiotensin system inhibitors (RAS inhibitors), such as angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB), effective in PD patients? Recommendation: We suggest the usage of RAS inhibitors (ACEI and ARB) in PD patients (GRADE 2C). CQ2: Icodextrin or glucose solution: which is more useful as a dialysate among patients with PD? Recommendation: We suggest using icodextrin when managing body fluids in PD patients (GRADE 2C). CQ3: Is it better to apply or not apply mupirocin/gentamicin ointment to the exit site? Recommendation: We suggest not applying mupirocin/gentamicin ointment to the exit sites of PD patients (GRADE 2C). CQ4: Which surgical approach is more desirable when a PD catheter is placed, open surgery or laparoscopic surgery? No recommendation. CQ5: Which administration route of antibiotics is better in PD patients with peritonitis, intravenous or intraperitoneal? Recommendation: We suggest intraperitoneal administration of antibiotics in PD patients with peritonitis (GRADE 2C). Note: The National Insurance does not currently cover intraperitoneal administration. CQ6: Is peritoneal dialysis or hemodialysis better as the first renal replacement therapy in diabetic patients? No recommendation. Conclusions: In the future, we suggest that society members construct their own evidence to answer CQs not brought up in this guideline, and thereby show the achievements of Japan worldwide.
AB - Background: This article is a duplicated publication from the Japanese version of “2019 JSDT Guidelines for Peritoneal Dialysis” with permission from the Japanese Society for Dialysis Therapy (JSDT). This clinical practice guideline (CPG) was developed primarily by the Working Group on Revision of Peritoneal Dialysis (PD) Guidelines of the Japanese Society for Dialysis Therapy. Recently, the definition and creation process for CPGs have become far more rigorous; traditional methods and formats no longer adhere to current standards. To improve the reliability of international transmission of our findings, CPGs are created in compliance with the methodologies developed by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) working group. Part 2 of this PD guideline is the first CPG developed by our society that conforms to the GRADE approach. Methods: Detailed processes were created in accordance with the Cochrane handbook and the GRADE approach developed by the GRADE working group. Results: Clinical question (CQ)1: Is the use of renin-angiotensin system inhibitors (RAS inhibitors), such as angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB), effective in PD patients? Recommendation: We suggest the usage of RAS inhibitors (ACEI and ARB) in PD patients (GRADE 2C). CQ2: Icodextrin or glucose solution: which is more useful as a dialysate among patients with PD? Recommendation: We suggest using icodextrin when managing body fluids in PD patients (GRADE 2C). CQ3: Is it better to apply or not apply mupirocin/gentamicin ointment to the exit site? Recommendation: We suggest not applying mupirocin/gentamicin ointment to the exit sites of PD patients (GRADE 2C). CQ4: Which surgical approach is more desirable when a PD catheter is placed, open surgery or laparoscopic surgery? No recommendation. CQ5: Which administration route of antibiotics is better in PD patients with peritonitis, intravenous or intraperitoneal? Recommendation: We suggest intraperitoneal administration of antibiotics in PD patients with peritonitis (GRADE 2C). Note: The National Insurance does not currently cover intraperitoneal administration. CQ6: Is peritoneal dialysis or hemodialysis better as the first renal replacement therapy in diabetic patients? No recommendation. Conclusions: In the future, we suggest that society members construct their own evidence to answer CQs not brought up in this guideline, and thereby show the achievements of Japan worldwide.
UR - http://www.scopus.com/inward/record.url?scp=85134008626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134008626&partnerID=8YFLogxK
U2 - 10.1186/s41100-021-00361-9
DO - 10.1186/s41100-021-00361-9
M3 - Article
AN - SCOPUS:85134008626
SN - 2059-1381
VL - 7
JO - Renal Replacement Therapy
JF - Renal Replacement Therapy
IS - 1
M1 - 46
ER -